شبكة المعلومات الجامعية

بسم اللّه الرحمن الرحيم

شبكة المعلومات الجامعية

التوثيق الالكتروني والميكروفيلم

شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم باللّه العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات

يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار

شبكة المعلومات الجامعية

بعض الوثائق الأصلية تالفة

بالرسالة صفحات

لم ترد بالأصل



The Impact of Pentoxifylline and Vitamin E on The Incidence and Severity of Radiotherapy-Induced Oral Mucositis and Dysphagia in Patients with Head and Neck Cancer

A Thesis

Submitted for Fulfillment of the Requirements
for
The Doctor of Philosophy (PhD) degree
In Pharmaceutical Sciences
(Clinical Pharmacy)
By

Rana Sayed Fouad

Master of Pharmaceutical sciences, 2014
Assistant lecturer of Clinical Pharmacy
Faculty of Pharmacy, Ain Shams University

2020

The Impact of Pentoxifylline and Vitamin E on The Incidence and Severity of Radiotherapy- Induced Oral Mucositis and Dysphagia in Patients with Head and Neck Cancer

A Thesis

Submitted for Fulfillment of the Requirements for

The Doctor of Philosophy (PhD) degree

In Pharmaceutical Sciences

(Clinical Pharmacy)

By

Rana Sayed Fouad, Msc

Assistant lecturer of Clinical Pharmacy

Faculty of Pharmacy, Ain Shams University

Under supervision of

Prof. Dr. Manal Hamed El Hamamsy, PhD

Professor of Clinical Pharmacy

Faculty of Pharmacy, Ain Shams University

Dr. Lamia Mohamed El Wakeel, PhD

Assistant Professor of Clinical Pharmacy

Faculty of Pharmacy, Ain Shams University

Dr. Amr Shafik Tawfik Saad, MD, PhD

Assistant Professor of Clinical Oncology

Faculty of Medicine, Ain Shams University

2020

بسم الله الرحمن الرحيم

نرفع درجات من نشاء و
فوق كل ذي علم عليم

صدق الله العظيم

سورة يوسف الأية: ٧٦

Acknowledgement

Foremost, I am deeply thankful to Allah by the grace of whom, this work was possible.

To my eternal proponent, my late husband Moataz: because I owe it all to you. Thank you.

A very special gratitude goes to Prof. Dr. Manal El Hamamsy, Professor of Clinical Pharmacy- Faculty of Pharmacy- Ain Shams University, for her continuous support of my PhD research.

I am very grateful to Dr. Lamia El Wakeel, Assistant Professor of Clinical Pharmacy- Faculty of Pharmacy- Ain Shams University, for her close supervision, immense knowledge and sincere help.

I would like to express my gratitude to Dr. Amr Shafik. Assistant Professor of Clinical Oncology- Faculty of Medicine- Ain Shams University, for his valuable guidance and sincere help.

My deep thanks goes to Dr. Mohamed Kelany, Lecturer of Clinical Oncology- Faculty of Medicine- Ain Shams University, for offering the opportunity to work under his supervision at the Clinical Oncology Department.

I would like to thank all the members of the Clinical Pharmacy Department, Ain Shams University for their unfailing assistance and motivational support.

My sincere appreciation goes to all the patients involved in this work. Your cooperation and adherence to the study protocol allowed me to accomplish this work.

I would like to express my deep appreciation to my mother and sisters who provided the emotional support to finish this work. Special thanks to my parents-in-law for their continuous support through the hardest time.

Last but by no means least, I would like to dedicate this work to my sons Omar and Ali. If it had not been for you, I would not have accomplished this work.

Table of Contents

Content	Page no.
List of Tables	i
List of Figures	ii
List of Abbreviations	iii
Abstract	2
Introduction	5
Review of literature	8
I. Head and neck Cancer	8
A. Definition, Epidemiology and Risk Factors	8
B. Pathogenesis of head and neck cancer	8
C. Clinical presentation and diagnosis of head and neck cancer	10
D. Prognosis and staging of head and neck cancer	11
E. Management of head and neck cancer	13
II. Radiotherapy-induced Toxicity in Head and Neck Cancer Patients	18
A. Adverse effects of radiotherapy	18
B. Pathophysiology of radiotherapy-induced toxicity	18
C. Grading of radiotherapy-induced toxicity	20
D. Radioprotective agents and radiation mitigators	20
E. Radiotherapy-induced toxicities	21
1. Oral mucositis	21
2. Dysphagia	23
3. Dry mouth and xerostomia	23
4. Dysgeusia	24
5. Radiation dermatitis	24
6. Osteoradionecrosis	25
III. Pentoxifylline	27
A. The pharmacodynamic activities of pentoxifylline	27
B. Pharmacokinetic properties of pentoxifylline	27
C. Clinical indications of pentoxifylline	29
D. The adverse effects of pentoxifylline	29
IV. Vitamin E	30
A. Vitamin E pharmacokinetic parameters	30
B. Clinical indications for vitamin E supplementation	31

Content	Page no.
C. Mechanism of action of vitamin E	31
D. Adverse effects of vitamin E	32
V. The role of pentoxifylline and vitamin E in radiotherapy-induced toxicity	33
VI. The role of the clinical pharmacist in the oncology setting	35
Aim of the work	40
Patients and methods	43
Results	55
Discussion	86
Conclusion, Limitations & Recommendations	95
References	99
Appendix	117
Arabic summary	140

List of Tables

Table	Page no.
Table 1: General definitions of different stages of head and neck cancer.	**13**
Table 2: Functional Oral Intake Scale (FOIS).	**47**
Table 3: Side effects-reporting and grading.	**50**
Table 4: Patients' demographic data in the study groups.	**58**
Table 5: Baseline clinical evaluation of the study groups.	**62**
Table 6: Binary logistic regression models fitted to describe the effect of the study drugs and patients' age on the incidence and severity of dysphagia.	**68**
Table 7: Binary logistic regression models fitted to describe the effect of the study drugs and patients' age on the incidence and severity of oral mucositis.	**69**
Table 8: Cox regression models used to compare dysphagia and oral mucositis onsets in both groups while adjusting for age.	**74**
Table 9: The effect of addition of the study drugs on duration of dysphagia and/or oral mucositis while adjusting for age.	**75**
Table 10: Achievement of locoregional disease control in both groups.	**76**
Table 11: Functional oral intake scale (FOIS) score and quality of life parameters of both groups by the end of follow-up.	**78**
Table 12: Binary logistic regression model fitted to assess the effect of pentoxifylline and vitamin E on patient hospitalization while adjusting for age.	**79**
Table 13: Need for unplanned radiotherapy break in both groups.	**81**
Table 14: Frequency of the various adverse events grade reported by patients in the study groups.	**82**
Table 15: Frequency of adverse events reported in the study groups.	**84**

List of Figures

Figure	Page no.
Figure 1: Carcinogenesis of head and neck malignancies	**9**
Figure 2: The chemical structure of pentoxifylline and its active metabolites	**28**
Figure 3: Vitamin E structure	**30**
Figure 4: CONSORT flow chart	**57**
Figure 5: Disease subsite distribution in the control group	**59**
Figure 6: Disease subsite distribution in the intervention group	**60**
Figure 7: Disease stage distribution in control and intervention groups	**61**
Figure 8: Box plot representing the distribution of baseline FOIS score in both groups	**64**
Figure 9: Box plot representing the distribution of baseline EQ-5D Index score in both groups	**65**
Figure 10: Box plot representing the distribution of baseline VAS score in both groups	**66**
Figure 11: Cox regression curve representing fraction of dysphagia free patients in both groups while adjusting for age.	**72**
Figure 12: Cox regression curve representing fraction of oral mucositis free patients in both groups while adjusting for age.	**73**
Figure 13: Common adverse events reported in more than 10% of the study population.	**83**

List of Abbreviations

EQ-5D	EuroQoL- 5-dimension
EQ-5D-3L	EuroQoL- 5-dimension- 3 level
FOIS	Functional oral intake scale
IQR	Inter-quartile range
NCI CTCAE v4.03	National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03
PO	Per oral
VAS	Visual analog scale

ABSTRACT